In this episode of The EY CEO Outlook series, EPS Global CEO Colin Lynch tells host Richard Curran the story of scaling internationally without external equity, making personal sacrifices to keep EPS Global afloat, and his plans to grow the company three-fold by 2025.For a company like EPS Global, it is a remarkably busy time to be in business. Founded in Ireland in 1999, EPS Global is a distributor of specialised IT components and semiconductors used in high-growth areas including data storage, cloud and the Internet of Things (IoT). Today, the company has annual sales of €100m, locations across 23 countries, and a plan to scale even further on the back of unprecedented demand for its services.Driving that growth is co-founder and CEO, Colin Lynch. An electrical engineer by training, Lynch spent 20-years as the company’s Business Development Director, expanding its global reach as far as China and building highly successful relationships with major brands including Alibaba, Google, and Bosch. Today, as CEO, he has a vision for further growth through external equity, M&A, and a possible IPO. They also discuss:Taking over the role of CEO after 20 years as Business Development Director – how he approached the new role and his priorities for the businessGlobal shortages of electrical components during a time of great demand, and the opportunities thereinThe future of business travel and client relations in a post-Covid business worldCreating a company culture based on trustHis experience in the EY Entrepreneur of the Year programme.

In this episode of the EY CEO Outlook series, Mark Rose Burke joins host Richard Curran to share her vision for Dublin city, her views on how to most effectively drive forward the changes required, and the top priorities and challenges facing business leaders in 2021 and 2022.There has been a lot of debate in recent years about the role that large cities will play in the how we work, live and play, particularly in a post-Covid landscape. As CEO of Dublin’s largest and most influential business group, representing over 1,300 companies, Mary Rose Burke has a very clear vision for how Ireland’s capital city should develop in order to make it a place where businesses and residents can thrive, and visitors enjoy spending time.  Originally from Co. Galway, Mary Rose joined Dublin Chamber as CEO in 2016 and has led the organisation throughout a period of great change for business and for large cities alike.  They also discuss: ·         Mary Rose’s experience and belief  in policy as a driver for real change ·         The fundamentals that make a city successful, and Dublin’s unique selling points. ·         The huge potential for growth within Dublin’s canal cordon. ·         Achieving the right balance of regional and Dublin-focussed development.  ·         Mary Rose’s leadership approach – “The measure of a good parish priest is how many bishops he creates”.  

Economic Eye host Richard Curran talks to EY Ireland Chief Economist, Neil Gibson, about current key economic indicators and the impact they are having on business across the entire country. In this episode, Neil outlines the findings of the Economic Eye Winter 2021 Forecast: ‘How people, prices, and planet will shape the all-island forecast’Topics include:· Why the all-Ireland economy is in far better health than expected as 2021 draws to a close· The growing need for more specific, targeted supports for those hardest hit in the pandemic· Inflation - the factors driving low inflation in recent years and why this is changing· Will interest rates hold steady or start to rise sooner rather than expected?· Why ‘purposeful growth’ has become the goal for policymakers, citizens, and business leaders alike.· How to balance financial growth and sustainability

When Francesca McDonagh joined Bank of Ireland as CEO in 2017, it was with a “mandate for change”. It was the only Irish bank to have repaid the taxpayer for its support during the financial crisis, and now there were new priorities. Francesca was tasked with widespread reform of BOI’s culture, systems, and business model. The opportunity, not just to transform Bank of Ireland but also to help change the banking sector in Ireland, is one that McDonagh not only relishes, but views as “a duty”. Implementing widespread transformation has involved some tough decisions. However, one thing that McDonagh intends to maintain and evolve is the “personal touch” when it comes to customer relationships, particularly during their journey through the bigger decisions in life such as buying a home a car, or planning for retirement. Richard and Francesca also discuss: ·         Bank of Ireland’s massive pivot to digital, the closure of branches and the future of day to day banking·         Francesca’s views on the residential property market and the mortgage system in Ireland·         The future of banking and competing with the new specialist providers entering the Irish market·         Why the normalisation of the State and Sector relationship is important as Irish banks increasingly compete for talent across Europe·          Francesca’s family background and personal views on hard work, resilience, and the benefits of diversity. 

In this episode of the EY CFO Outlook podcast series, Group CFO for Open Orphan, Leo Toole tells host Vincent Wall about how a highly specialised approach to clinical trials is proving very successful for a young Irish company. He also describes how he is helping Open Orphan to “control [its] own destiny…by driving sustainable performance, profit, and cashflow”. Open Orphan is a Clinical Research Organisation (CRO) with a difference. While most CROs recruit people who are already infected with a disease for their trials, Open Orphan takes healthy patients, gives them the infection, and then runs the trial. This model, according to the company’s CFO Leo Toole, allows them “to get better data sooner, better drugs sooner, [and therefore] better outcomes sooner for patients”.  As a result, the clinical and operation risks for Open Orphan’s partners are radically reduced. And, with big pharma currently investing heavily in infectious disease programmes, this young company is now growing rapidly and is already profitable. Leo and Vincent also discuss; ·         The world-first COVID 19 trial which Open Orphan is delivering is delivering on behalf of the British government  ·         Leo’s views on the mindset of a successful CFO·         Leveraging technology to increase efficiency and drive productivity ·         The importance of developing a strong communication profile with investors  What Leo has learned about avoiding ‘analysis paralysis’ from Open Orphan’s dynamic co-founder, Cathal Friel. 

It is an interesting time to be overseeing the management and evolution of Ireland’s public transport network. Not only has the pandemic dramatically reduced passenger numbers on trains, trams, buses and taxis, at least temporarily, but the rapid move towards environmentally sustainable modes of transport is also introducing new and interesting challenges. As CEO of the National Transport Authority (NTA), Anne Graham is tasked with helping to develop solutions for these challenges and others, while also creating strategies to build the public transport system of the future. In this episode of the EY CEO Outlook Podcast, Anne Graham tells host Richard Curran the story of her rise through the public service to the role she holds today, and her vision for the public transport system of tomorrow. They discuss:·         The challenge of providing public transport in rural areas, and how residential planning must play a role. ·         The planned electrification of the bus fleet, battery range, and future technology·         How to encourage more women into engineering·         Why the NTAs mission around sustainability is helping drive talent recruitment ·         The concept of ‘mobility as a service’ and making one ticket allow access to several modes of transport  

In this episode of the EY  CFO Outlook podcast series, Andy Cronin tells host Vincent Wall the story of a Avolon’s remarkable growth from Dublin start-up to a world leader in aircraft leasing in just a few short years. They discuss:·         How Andy, an engineer, became the co-founder and CFO of an aircraft leasing company·         The story of Avolon’s IPO and his experience of running the finance function of a public company versus a private one·         Raising capital and how Avolon has achieved a credit rating on a par with major banks·         Environmental sustainability and why Avolon is investing heavily in electric ‘flying taxis’  ·         Why Ireland enjoys a ‘monopoly position’ in the aircraft leasing sector·         Why data pays a critical role in Avolon’s success. 

In this episode of The EY CEO Outlook podcast, ICON CEO Steve Cutler tells host Richard Curran the story of ICON’s rise from Irish start-up to global leader in a challenging and competitive field, and his role in that journey. A former Australian rugby international, Cutler sees many similarities between playing on the pitch and leading a contract research organisation  (both are competitive “contact sports”), and he describes how his former career has influenced the style and success of his leadership approach.

In this episode of the EY CFO Outlook podcast, Kenmare Resources Finance Director, Tony McCuskey tells host, Vincent Wall the compelling story of an Irish company’s rise to the top of the exploration industry. It is a journey involving hostile environments, working with local governments and communities , maintaining relationships with partners and shareholders, and personal resilience.“We didn’t have any physical assets, what we had was a dream”. When Tony McCluskey joined Kenmare Resources in 1991 it was still a relatively small Irish exploration company. Today it is one of the world’s leading producers of titanium materials and zircon, quoted on the London stock exchange, and with a market capitalisation of £500 million.  The story of how Kenmare Resources has grown into what it is today is a fascinating one, but it has not been without its crisis points. Commodity prices can rise and fall sharply, and Kenmare Resources almost fell into the hands of new owners during a particularly rocky period. Leading the company’s finance function throughout that time, McCluskey clearly remembers the determination, perseverance, and support that saved them.They also talk about:·       Tony’s upbringing in Co. Kilkenny and why he always wanted to be part of a business·       His experience working in rural Mozambique·       The dramatic collapse in mineral prices that almost led to the loss of the company to new owners·       The importance of benefiting the community in which you run operate – funding schools, hospitals and agricultural programmes·       His key priorities as CFO. 

As a young science graduate, Audrey Derveloy’s goal was to have a positive impact on society. Now, as a leader of a global medicines company during a world-wide pandemic, that dream is being realised.  Novartis employs 1,400 people in Ireland, and the company uses innovative science and digital technologies to create transformative treatments in areas of great medical need such as Cardiology, Oncology and Immunology. Having spent several years in leadership roles at Novartis in France, Audrey was offered the role of General Manager and Country President of Novartis Ireland in early 2020, just before the COVID-19 pandemic began.  In this episode of The EY CEO Outlook Podcast, Audrey Derveloy, General Manager of Novartis Ireland, tells host Richard Curran about her aspirations as a young medical student, her lifelong love of science, moving her family to Ireland to run Novartis’ operations there, and her vision for the future of medicine.They also discuss: ·        Why COVID-19 is a valuable opportunity to build trust in the Pharma sector ·        Novartis’ footprint in Ireland and what kind of medicines it makes in this country ·        Why the future of Pharma lies in intelligent data ·        Audrey’s views on improving Irelands’ Pharma regulatory landscape  ·        Why the State may need to collaborate more with the pharma sector to develop innovative medicines.